Parecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects

Journal of Clinical Gastroenterology

Volumn 38, Issue 7, 2004, Pages 575-580

  Harris, Stuart I ^a   Stoltz, Randall R ^b   LeComte, Dianne ^c   Hubbard, Richard C ^c  

^a Seaview Research   (United States)

^b GFI Pharmaceutical Services Inc   (United States)

^c PFIZER INC   (United States)

Author keywords

Cyclooxygenase 2; Gastrointestinal; Parecoxib sodium

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; KETOROLAC; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; ROFECOXIB; VALDECOXIB;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DIZZINESS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DYSPEPSIA; EDEMA; ENDOSCOPY; ENZYME INHIBITION; EYELID EDEMA; FEMALE; FLATULENCE; GASTRODUODENAL ULCER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MUCOSA; GLOSSITIS; HUMAN; INFLAMMATION; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH EROSION; STOMATITIS; VOMITING;

ADULT; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DUODENAL ULCER; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTRIC MUCOSA; HUMANS; ISOXAZOLES; KETOROLAC; MALE; MIDDLE AGED; PAIN; TREATMENT OUTCOME;

EID: 3242714039     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200408000-00007     Document Type: Article

References (28)

1. Borda IT. NSAIDs: a profile of adverse effects. Philadelphia: Hanley and Belfus Inc.; 1995.
2. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs: differences and similarities. N Engl J Med. 1991;324:1716-1725.
3. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787-796.
4. Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769-772.
5. Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy. Recognition and response. Arch Intern Med. 1987;147:2093-2100.
6. Reinhart DI. Minimising the adverse effects of ketorolac. Drug Saf. 2000;22:487-497.
7. Gillis JC, Brogden RN. Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs. 1997;53:139-188.
8. Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA. 1996;275:376-382.
9. Gierse JK, McDonald JJ, Hauser SD, et al. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem. 1996;271:15810-15814.
10. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921-1928.
11. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol. 2001;96:1019-1027.
12. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc. 1999;74:1095-1105.
13. Geis GS. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Scand J Rheumatol. 1999;26 (Suppl 56):31-36.
14. Talley JJ, Brown DL, Carter JS, et al. 4-[5-Methyl-3-phenylisoxazol-4-yl] -benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem. 2000;43:775-777.
15. Noveck RJ, Laurent A, Kuss M, et al. Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals. Clin Drug Invest. 2001;21:465-476.
16. Harris SI, Kuss M, Hubbard RC, et al. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther. 2001;23:1422-1428.
17. Stoltz RR, Harris SI, Kuss ME, et al. Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am J Gastroenterol. 2002;97:65-71.
18. Desjardins PJ, Grossman EH, Kuss ME, et al. The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered pre-operatively. Anesth Analg. 2001;93:721-727.
19. Rasmussen GL, Steckner K, Hogue C, et al. Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. Am J Orthop. 2002;31:336-343.
20. Barton SF, Langeland FF, Snabes MC, et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute post-operative pain following gynecologic laparotomy surgery. Anesthesiology. 2002;97:306-314.
21. Lanza FL, Rack MF, Royer GL, et al. Gastro-intestinal effects of ibuprofen, naproxen, and aspirin in normal volunteers. Clin Trials J. 1986;23:168-177.
22. Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal anti-inflammatory agents. Am J Med. 1984;77:19-24.
23. Lanza FL, Royer GL Jr, Nelson RS, et al. The effects of ibuprofen, indomethacin, aspirin, naproxen, and placebo on the gastric mucosa of normal volunteers: a gastroscopic and photographic study. Dig Dis Sci. 1979;24:823-828.
24. Santucci L, Fiorucci S, Patoia L, et al. Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens. Dig Dis Sci. 1995;40:2074-2080.
25. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
26. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. Vigor Study Group. N Engl J Med. 2000;343:1520-1528.
27. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-249.
28. Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol. 1996;91:2080-2086.